Folate and choline metabolism gene variants and development of uterine cervical carcinoma

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 596-600

  Mostowska, Adrianna ^a   Myka, Martyna ^a   Lianeri, Margarita ^a   Roszak, Andrzej ^b   Jagodziński, Pawel P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Greater Poland Cancer Centre Poznan   (Poland)

Author keywords

BHMT; Cervical cancer; Protective factor

Indexed keywords

BETAINE HOMOCYSTEINE METHYLTRANSFERASE; DNA; FOLIC ACID;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL EVALUATION; CLINICAL EXAMINATION; DNA METHYLATION; FOLATE METABOLISM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; NONHUMAN; POLAND; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; UTERINE CERVIX CARCINOMA;

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADULT; ALLELES; BETAINE-HOMOCYSTEINE S-METHYLTRANSFERASE; CHOLINE; FEMALE; FERREDOXIN-NADP REDUCTASE; FOLIC ACID; GENOTYPE; HUMANS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MIDDLE AGED; MODELS, BIOLOGICAL; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

EID: 79955821925     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.02.007     Document Type: Article

References (46)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(S3):11-25.
3. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
4. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
5. Münger K., Baldwin A., Edwards K.M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004, 78:11451-11460.
6. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(Suppl 1):S16-S24.
7. Magnusson P.K., Sparen P., Gyllensten U.B. Genetic link to cervical tumours. Nature 1999, 400:29-30.
8. Hemminki K., Dong C., Vaittinen P. Familial risks in cervical cancer: is there a hereditary component?. Int J Cancer 1999, 82:775-781.
9. Luczak M.W., Jagodzinski P.P. The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006, 44:143-154.
10. Flatley J.E., McNeir K., Balasubramani L., et al. Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. Cancer Epidemiol Biomarkers Prev 2009, 18:2782-2789.
11. Cantoni G.L. S-adenosylmethionine; a new intermediate fordem enzymatically from l-methionine and adenosinetriphosphate. J Biol Chem 1953, 204:403-416.
12. Li Y.N., Gulati S., Baker P.J., Brody L.C., Banerjee R., Kruger W.D. Cloning, mapping and RNA analysis of the human methionine synthase gene. Hum Mol Genet 1996, 5:851-858.
13. Garrow T.A. Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase. J Biol Chem 1996, 271:22831-22838.
14. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995, 10:111-113.
15. Hum D.W., Bell A.W., Rozen R., MacKenzie R.E. Primary structure of a human trifunctional enzyme: isolation of a cDNA encoding methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase. J Biol Chem 1988, 263:1594650.
16. Brody L.C., Conley M., Cox C., et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002, 71:1207-1215.
17. Leclerc D., Wilson A., Dumas R., et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A 1998, 95:3059-3064.
18. Paz M.F., Avila S., Fraga M.F., et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002, 62:4519-4524.
19. Dong L.M., Potter J.D., White E., et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008, 299:2423-2436.
20. Liu H., Jin G., Wang H., et al. Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. Lung Cancer 2008, 61:21-29.
21. Kang S., Kim J.W., Kang G.H., et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005, 96:173-180.
22. Hazra A., Wu K., Kraft P., Fuchs C.S., Giovannucci E.L., Hunter D.J. Twenty-four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study. Carcinogenesis 2007, 28:1510-1519.
23. Xu X., Gammon M.D., Wetmur J.G., et al. B-vitamin intake, one-carbon metabolism, and survival in a population-based study of women with breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:2109-2116.
24. Castellsague X., Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003, 20-28.
25. Magnusson P.K., Lichtenstein P., Gyllensten U.B. Heritability of cervical tumours. Int J Cancer 2000, 88:698-701.
26. Hemminki K., Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol BiomarkersPrev 2006, 15:1413-1414.
27. Xu X., Gammon M.D., Zeisel S.H., et al. High intakes of choline and betaine reduce breast cancer mortality in a population-based study. FASEB J 2009, 23:4022-4028.
28. Weisberg I.S., Park E., Ballman K.V., et al. Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis 2003, 167:205-214.
29. Mostowska A., Hozyasz K.K., Wojcicki P., Dziegelewska M., Jagodzinski P.P. Associations of folate and choline metabolism gene polymorphisms with orofacial clefts. J Med Genet 2010, 47:809-815.
30. Ananth C.V., Elsasser D.A., Kinzler W.L., et al. Polymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: risk of placental abruption. Mol Genet Metab 2007, 91:104-110.
31. Fredriksen A., Meyer K., Ueland P.M., Vollset S.E., Grotmol T., Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat 2007, 28:856-865.
32. Boyles A.L., Billups A.V., Deak K.L., et al. NTD Collaborative Group Neural tube defects and folate pathway genes: family-based association tests of gene-gene and gene-environment interactions. Environ Health Perspect 2006, 114:1547-1552.
33. Goodman M.T., McDuffie K., Hernandez B., et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 2001, 10:1275-1280.
34. Sull J.W., Jee S.H., Yi S., et al. The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol 2004, 95:557-563.
35. Nandan N.K., Wajid S., Biswas S., et al. Allelic variations in 5, 10-methylenetetrahydrofolate reductase gene and susceptibility to cervical cancer in Indian women. Drug Metab Lett 2008, 2:18-22.
36. Zoodsma M., Nolte I.M., Schipper M., et al. Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet 2005, 116:247-254.
37. Tong S.Y., Lee J.M., Song E.S., et al. The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. Cancer Causes Control 2010, 21:23-30.
38. Lambropoulos A.F., Agorastos T., Foka Z.J., et al. Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett 2003, 191:187-191.
39. Gerhard D.S., Nguyen L.T., Zhang Z.Y., Borecki I.B., Coleman B.I., Rader J.S. A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. Gynecol Oncol 2003, 90:560-565.
40. Rao G.G., Kurien A., Gossett D., Griffith W.F., Coleman R.L., Muller C.Y. A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis. Gynecol Oncol 2006, 101:250-254.
41. Kohaar I., Kumar J., Thakur N., et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population. Biomarkers 2010, 15:61-68.
42. James S.J., Melnyk S., Pogribna M., Pogribny I.P., Caudill M.A. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002, 132:2361S-2366S.
43. Szalmás A., Kónya J. Epigenetic alterations in cervical carcinogenesis. Semin Cancer Biol 2009, 19:144-152.
44. Ueland P.M. Choline and betaine in health and disease. J Inherit Metab Dis 2011, 34:3-15.
45. Li F., Feng Q., Lee C., et al. Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization. Mol Genet Metab 2008, 94:326-335.
46. Poirier L.A. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr 2002, 132:2336S-2339S.